GERD Re-Treatment Should Be Assessed In Enteryx Postmarket Study – Panel
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's Enteryx is approvable for gastroesophageal reflux disease, contingent on a placebo-controlled, postmarket study, FDA's Gastroenterology & Urology Devices Panel concluded Jan. 17 in Gaithersburg, Md
You may also be interested in...
Boston Scientific Enteryx GERD Device Clears FDA With Limited Indication
Patients who respond to pharmacological treatments for gastroesophageal reflux disease (GERD) have a new therapeutic alternative in Boston Scientific's Enteryx injectable treatment system
Boston Scientific Enteryx GERD Device Clears FDA With Limited Indication
Patients who respond to pharmacological treatments for gastroesophageal reflux disease (GERD) have a new therapeutic alternative in Boston Scientific's Enteryx injectable treatment system
Boston Scientific Beefs Up Endosurgery Unit With Enteric Medical
Boston Scientific appears to be hedging against uncertainties in its Scimed interventional cardiology business by strengthening its product pipeline in other units, particularly its Endosurgery group